Phaseline

Companies › Sling Therapeutics

Sling Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Ophthalmology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
linsitinib
Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor
IGF1R, INSRPhase 3Thyroid Eye Disease, TED; Thyroid Eye DiseaseJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06112340linsitinibPhase 2Thyroid Eye DiseaseMetabolic and endocrineJun 2026
NCT07753603linsitinibPhase 3Thyroid Eye Disease, TEDOphthalmologyJun 2028

Targets

IGF1R (1) INSR (1)

Companies with the same targets

Innovent Biologics (Suzhou) OHB Neonatology Amgen Candid Therapeutics Viridian Therapeutics Minghui Pharmaceutical (Hangzhou) Zai Lab (Shanghai) Novo Nordisk Gan & Lee Pharmaceuticals. Sanofi

Companies built like this

Viridian Therapeutics Nacuity Pharmaceuticals ReGenTree Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.